Biotech Values

[poorgradstudent]

Ok, AMGN demonstrated non-inferiority, but I can’t see any commercial consequence from this study.

At least this is scientifically interesting and we can conclude that the isotype of the antibody does not make a meaningful contribution to efficacy. We've discussed it on the board and had some data in support, but this head to head trial is the best type of data.